BPM
ENTA icon

Bowling Portfolio Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Bowling Portfolio Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,681
Closed -$447K – 340
2019
Q1 		$447K Sell
4,681
-19
-0.4% -$1.7K 0.07% 301
2018
Q4 		$333K Sell
4,700
-9,993
-68% -$766K 0.06% 314
2018
Q3 		$1.26M Sell
14,693
-8,464
-37% -$848K 0.18% 202
2018
Q2 		$2.68M Buy
+23,157
New +$2.31M 0.38% 79

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bowling Portfolio Management's ENTA Position: Q2 2019 in Review

Bowling Portfolio Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 4,681 shares — an estimated $447K sold.

Bowling Portfolio Management first reported a position in ENTA in Q2 2018 and held it in 4 quarters. The position peaked at $2.68M in Q2 2018. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • Bowling Portfolio Management reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Bowling Portfolio Management sold 4,681 Enanta Pharmaceuticals shares in Q2 2019, an estimated $447K.
  • Bowling Portfolio Management first reported a position in Enanta Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Bowling Portfolio Management's Enanta Pharmaceuticals position peaked at $2.68M in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Bowling Portfolio Management's 13F filing for Q2 2019, filed 25 Jul 2019.